

AL-LAD L-tartrate Pure
AL-LAD L-tartrate properties
Synonym: 6-allyl-6-nor-lysergic acid diethylamide hemi-L-tartrate
CAS Number: 65527-61-9
Formula: (8β)-N,N-diethyl-6-(prop-2-en-1-yl)-9,10-didehydroergoline-8-carboxamide hemi-L-tartrate
Molar mass: 424.5 g/mol
Purity: >97%
€4,400.00
* The information on this page is a summary and is not intended to cover all available information about this medication. It does not cover all possible uses, directions, precautions, drug interactions or adverse effects and is not a substitute for the expertise and judgment of your healthcare professional.
AL LAD L-Tartrate – Extended Product Description for Scientific Research
Introduction
AL LAD L-Tartrate (6-allyl-6-nor-lysergic acid diethylamide L-tartrate) is a semi-synthetic lysergamide that shares structural similarities with LSD. This compound is used exclusively in controlled research environments, primarily for pharmacological and neurochemical studies. This product sheet contains detailed information on specifications, applications, and safety protocols.
Chemical Specifications
- Systematic name: (6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide L-tartrate
- Molecular formula: C₂₂H₂₉N₃O₂·C₄H₆O₆
- Molecular mass: 511.55 g/mol
- Purity: ≥99% (HPLC-UV)
- Appearance: White to light beige crystalline powder
- Solubility: 20 mg/ml in water (at 20°C), freely soluble in methanol
- Melting point: 185–190°C (with decomposition)
Stability and Storage
- Storage conditions: -20°C, sealed in amber vials under argon
- Shelf life: 36 months when stored correctly
- Sensitivity: Light sensitive, oxygen sensitive, hygroscopic
Potential Research Applications
AL-LAD L-tartrate is being studied for:
- Serotonergic receptor binding (with emphasis on 5-HT₂A)
- Structural-functional relationships within lysergamides
- Neuropharmacological mechanisms of hallucinogens
- Behavioral studies in animal models (where permitted)
Safety Protocol
Personal Protection
- Double nitrile gloves
- Protective clothing (Type 5/6)
- Closed safety glasses
- FFP3 respiratory protection
Working conditions
- Only handle in fume cupboard (Type B2)
- Use explosion-proof equipment
- Strict access and area control
First aid
- Eye contact: Rinse with water for at least 30 minutes.
- Skin contact: Wash with poloxamer solution
- Inhalation: Seek immediate medical evaluation
Analytical Certification
Each batch contains:
- Certificate of Analysis (COA)
- HPLC-UV chromatogram (254 nm)
- HRMS data (ESI+ mode)
- Karl Fischer water content
- Residual solvent profile
- NMR spectra (¹H and ¹³C)
- Chiral purity analysis
Regulatory Framework
- Classified under the Dutch Opium Act (List I)
- Only available to licensed research institutions
- Prohibited for human administration
- Subject to international export restrictions
Order and Delivery Information
- Packaging options:
- 10 mg (±0.5 mg) in argon-flushed ampoule
- 50 mg (±1 mg) in amber HPLC vial
- Transport: Chilled (2–8°C) with temperature monitoring
- Documentation: Full traceability from synthesis to delivery
Quality control
- Production according to GMP guidelines
- Triple quality control:
- In-process analysis
- Final product control
- Independent validation
- Stability study according to ICH Q1A
Scientific References
- Nichols et al. (2015) – Pharmacological studies of lysergamides
- Brandt et al. (2016) – Receptor binding profiles
- EU NPS reports (2019–2023)
Disclaimer
This product is intended only for authorized scientific research under controlled laboratory conditions. Use is only permitted under applicable laws and regulations. The end user is fully responsible for compliance with legal obligations.
1cP-LSD 150 MCG Art Blotters O-DSMT 50mg Pellets 1V-LSD 150 MCG Blotters 6-CL-ADBA 2-CMC 250mg pellets